Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen Pharmaceutical K.K.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have Crohn's Disease (CD) or fistulizing CD of at least 3 months duration (defined as a minimum of 12 weeks), with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy
Have moderate to severe CD as assessed by CDAI components of stool frequency (SF), and abdominal pain (AP) scores, and endoscopic evidence
Have screening laboratory test results within the protocol specified parameters
A female participant of childbearing potential must have a negative urine pregnancy test result at screening and baseline
Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD
You may not be if
Has complications of CD, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation
Unstable doses of concomitant Crohn's disease therapy
Receipt of Crohn's disease approved biologic agents, investigational agents, or procedures outside of permitted time frame as specified in the protocol
Prior exposure to p40 inhibitors or p19 inhibitors
Any medical contraindications preventing study participation
